The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the role of tafasitamab in the treatment of lymphoma. Dr Collins highlights the success of tafasitamab in combination with lenalidomide (tafa-len) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) as well as the ongoing InMIND trial investigating tafa-len plus rituximab in R/R follicular lymphoma (FL; NCT04680052). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene
